Glaxo’s spin on hidden Seroxat data scandal and Alastair Benbow’s memory loss between October 1998 and May 2003

Let’s take a step back, shall we.

It’s worth looking at what happened and when – because Alastair Benbow seems to have forgotten something…It was only in February 2003 that GSK finally submitted some clinical trial data to the MHRA showing that paroxetine caused suicidal ideation, and even then data from adult and paediatric trials were merged.

Full data from the clinical trials in children, demonstrating a causal link between paroxetine and suicidal ideation and behaviour, was finally submitted by GSK to the MHRA in May 2003a month before the company was due to submit an application for the drug to be licensed for use with children. [So Glaxo was still going to apply for a licence for use in children – in June 2003?]

GSK has rejected claims that it withheld information. Dr Alastair Benbow, medical director for GSK Europe, said: “We firmly believe we acted properly and responsibly in first carrying out this important clinical trials programme and then informing the regulatory agencies when we identified a potential increased risk of suicidal thinking and behaviour in patients under 18.”

So what Benbow is saying is that Glaxo did good – giving the MHRA, in May 2003, data from the trials and telling the MHRA there was a “potential risk”.

May 2003?

By my reckoning that’s four and a half years too late.

In October 1998 an internal, confidential SmithKline Beecham document about studies 329 and 377 was issued. Studies 329 and 377 tried to prove Seroxat/Paxil worked in children. In summary it said “… the data do not support a label claim for the treatment of Adolescent Depression… efficacy had not been demonstrated.” Specifically about Study 329 “…the study failed to demonstrate a statistically significant difference from placebo on the primary efficacy measures.”

In other words – it didn’t work.

About Study 377 we read “… failed demonstrate [sic] any separation of Seroxat/Paxil from placebo.”

In other words – it didn’t work.

“Data from these 2 studies are insufficiently robust to support a label change and will therefore not be submitted to the regulatory authorities.”

Feel free to download a copy of this document and read the rest of the interesting conclusions (especially page 6) – SB internal

Now we move on to March 1999, to a fuller manuscript of Study 329 being prepared for publication. This was written by Sally K Laden but was attributed to Marty Keller, Neil Ryan and colleagues. (I believe this is what is known as ghostwriting).Please download a copy of this manuscript – Sally/Marty draft 3 -If you go page 4 you will see the conclusion reads “Paroxetine is a safe and effective treatment of major depressive disorder in the adolescent patient.”

You can see that Sally/Marty’s spin has quickly moved on from that of SmithKline Beecham only 5 months previously. In fact you might be forgiven for wondering how these two different conclusions could be reached from the same data…

Now on to March 2001 – internally at least SmithKline Beecham seem to have understood what the data from Study 329 really said. In an email to Cohn and Wolfe, the company said: “Originally we planned to do extensive media relations surrounding this study [329] until we viewed the results. essentially the study did not really show Paxil was effective in treating adolescent depression, which is not something we want to publicize.” Download a copy here – SB to Cohn Wolfe

However, by August 2001 SmithKline Beecham Paxil Product Management was writing to all sales representatives selling paxil and telling them about Marty Keller’s “cutting edge, landmark study which was the first to compare efficacy of an SSRI and a TCA with placebo in the treatment of major depression in adolescents. Paxil demonstrates REMARKABLE Efficacy and Safety in the treatment of adolescent depression.” Download this memo here – Sales reps memo

As I said none of this is new.

The last Panorama programme, Secrets of the Drug Trials was where all of this first broke.

Someone should have faced criminal charges.

So what do you say Alastair? – is four and a half years a timely response?

I wonder how many children and adolescents died in those four and a half years between October 1998 and May 2003 becuase they took Seroxat/Paxil?

You tell me.

7 Responses to “Glaxo’s spin on hidden Seroxat data scandal and Alastair Benbow’s memory loss between October 1998 and May 2003”

  1. BOB FIDDAMAN Says:

    And are we forgetting Alasdair Breckenridge on BBC TV’s Panorama?

    Shelley Jofre: Might Criminal charges be brought?

    Breckenridge: That is a possibility

    How is it a possibility? Surely he knew the law back then? If he didn’t then what is he doing as Chairman of the MHRA?

    Fid

  2. truthman30 Says:

    It was never a possibility Fid..
    The UK government and the MHRA have too many vested interests in GSK ..
    They no better than to bite the hand that feeds them..
    GSK killing these kids with Seroxat is merely a “side effect” of the system..
    A system which protects the interests of big business and pharma before the health, well being and lives of the public..
    It just goes to show that human life has no value in a corporate owned regulatory system…
    This turn of events also goes way beyond Seroxat and GSK..
    People in the UK should be aware that their government condones corporate crime…
    The deeper the pocket , the higher above the law a corporation becomes..
    Very disturbing..

  3. Matthew Holford Says:

    It looks like there’s going to be another cover-up. There’s a lot of information out there, now, so the MHRA could never claim that there wasn’t a withholding of data. But it’s done the next best thing: decide that that’s not sufficient to establish culpability. Anything that contradicts that position will be ignored, and nothing will be done to correct the underlying issues that the industry has, in order to ensure that it does not happen again. We will have another Seroxat, probably in the not-too-distant future, and that will be treated as an isolated incident, too – a failure to communicate, requiring more legislation.

    Now we’re going to have some new law, which will probably not address the issue, particularly as, per Pinbenbow’s expectation, the Worshipful Company is likely to be involved in the consultation. Yet another conflict of interest to add to the ever-growing list. Besides which, are you happy with the idea that the MHRA will be policing this new law? I’m not. The MHRA and the industry are not acting in concert in the interests of the public. We are merely the end user of its product.

    We now know that GSK/SKB knew of the risks long before it made them public. That is a fact acknowledged on an official level. We are led to believe that the MHRA knew nothing. I find that utterly incredible. GSK’s admission, in 2003, was hardly the first that the MHRA had heard of suicidality as a side effect. Healey, for one, had been telling them about it for 10 years, by that time.

    The MHRA has failed us, people. And it continues to fail us. That is the simple, inescapable truth. I don’t know what motivated this failure, incompetence or corruption, but I know it failed.

    Matt

  4. truthman Says:

    What amazes me about this complete abortion of justice and human rights is, if you read through the GSK investors online forum you will see that all they are concerned about is the share price , dead children haven’t even been mentioned..

    http://www.iii.co.uk/investment/detail/?display=discussion&code=cotn%3AGSK.L&threshold=0&it=le&pageno=1

  5. Lynn Says:

    petition – Divest from GSK!

  6. 3 questions for JP Garnier… who, after all “has nothing to hide” « seroxat secrets… Says:

    […] Glaxo’s spin on hidden Seroxat data scandal and Alastair Benbow’s memory loss between Oc… […]

  7. GSK Lawyers target Seroxat campaigner Bob Fiddaman - what next? « seroxat secrets… Says:

    […] Glaxo’s spin on hidden Seroxat data scandal and Alastair Benbow’s memory loss between Oc… […]


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: